Gamma Biosciences, a life sciences platform established by KKR (KKR) to address the advanced therapy bioprocessing market, announced that it has entered into an agreement with Merck KGaA (MKGAY), whereby Merck KGaA will acquire Gamma operating company Mirus Bio for $600M in cash. Mirus Bio is a provider of innovative transfection solutions used for the delivery of genetic material into cells. The company offers a comprehensive portfolio of RUO and GMP reagents and enhancers based on proprietary, multi-component technology. Its products deliver high-performance and cost-effective transfection for a variety of applications, from research through virus manufacturing at scale to address rapidly growing cell and gene therapy applications in AAV & LV. Gamma acquired a controlling stake in Mirus Bio in 2021 and has worked closely with the company to support its growth and scale-up, including the launch of flagship products VirusGEN GMP and RevIT AAV Enhancer for large-scale therapeutic adeno-associated virus and lentivirus production. The transaction is expected to be completed in the third quarter of 2024, subject to US regulatory approvals, as well as other customary closing conditions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KKR:
- Blackstone (NYSE:BX) Extends Equity Ownership to Employees
- KKR provides $300M corportate credit facility to Origis Energy
- KKR put volume heavy and directionally bearish
- KKR acquires Class A logistics property in Nashville Airport submarket, no term
- California blocks PG&E proposal for minority sale, Bloomberg says
